Search global stocks & ETFs...Ctrl K
Learn Mode
VRTX
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
3.88
Good
Valuation Score
Key Score
3.00
Average
Management
1.00
Very Bad
Growth
5.00
Very Good
Profitability
3.00
Average
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
4.00
Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$528.04
Baseline
High
$673.05
▲
27.46%
Avg
$558.75
▲
5.82%
Low
$333.30
▼
-36.88%
Analyst Ratings based on 40 Analysts
Strong Buy
1333%
Buy
2050%
Hold
615%
Sell
000%
Strong Sell
103%
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).Read More